Second solid tumors are well known late complications after bone marrow transplantation. Treatment strategies are ill defined. We retrospectively evaluated treatment and outcome in a single institution. From August 1974 to July 1996, six solid tumors were observed in five of 387 patients 2 to 13 years after BMT, corresponding to a probability of developing a second solid tumor of 9% (1-17%, 95 CI) at 15 years: these comprised endometrial carcinoma, carcinoma of the thyroid gland, cervical carcinoma, sarcoma of the small intestine, osteosarcoma of the tibia and ovarian carcinoma. All five patients were treated as intensively as they would be without a history of BMT. At last follow-up four of the five patients were alive and without signs of tumor. We postulate that second solid tumors after BMT should be treated as de novo tumors. Early detection based on consequent clinical follow-up of the transplant patients might explain the relatively good outcome. Bone Marrow Transplantation (2000) 25, 895-898.
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for many hematological disorders of the bone marrow. 1, 2 With improvements in the results, the number of long-term survivors increases continuously. Therefore, late complications have become a concern. 3, 4 Among these, three types of malignancies have been described: post-transplant lymphoproliferative disorders, secondary leukemias and second solid tumors. Lymphoproliferative diseases are mainly observed early post transplant during immunosuppressive therapy, secondary leukemias occur 3-5 years post transplant and second solid tumors appear mostly 5 or more years post transplant. [5] [6] [7] The risk of long-term survivors for developing a second tumor at 15 years after transplantation is as high as 21%. 8 Treatment options for lymphoproliferative disease and secondary leukemias are reduction or discontinuation of immunosuppressive therapy, infusions of donor lymphocytes or retrans- plantation. 9, 10 In contrast, few data exist about treatment of second solid tumors and prognosis is considered to be poor. Here, we present the outcome of five patients who have been appropriately treated for their second solid tumor.
Patients and methods

Study design
All consecutive recipients of allogeneic stem cell transplantation, treated between August 1974 and July 1996 in Basel, were included in this retrospective cohort study. All charts were reviewed for evidence of second solid tumors, details of the tumor, treatment and outcome.
Patient population and transplant regimens
Three hundred and eighty-seven patients were transplanted with a median age at transplantation of 26 years (range 1-58 years); 55% of the patients were male. One hundred and fifteen patients (30%) were treated for acute myeloid leukemia, 88 (23%) for acute lymphocytic leukemia, 91 (24%) for chronic myeloid leukemia, 50 (13%) for severe aplastic anemia and 43 patients (10%) for other hematological diseases. Donors were HLA-identical siblings (91%), matched unrelated (4%), twins (4%) and mismatched related (1%). Median follow-up was 7 years (range 1.5-23).
Patient care remained relatively constant throughout the whole observation period and has been previously described in detail. 11 Pretransplant conditioning consisted either of cyclophosphamide, with or without VP-16 and total body irradiation, fractionated or as a single dose or of busulfan and cyclophosphamide for malignant disorders and cyclophosphamide alone for aplastic anemia. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate alone until 1979 and mostly in combination with cyclosporine subsequently. Between 1985 and 1989 most grafts were T cell depleted using a counterflow elutriation.
Statistical evaluation
The Kaplan-Meier estimator was used to calculate survival probability and probability of developing a second solid tumor. Years after transplantation (patients at risk) Figure 1 The probability of developing a second cancer at 15 years after BMT is 9 Ϯ 8%.
Results
Survival
At the time of last observation, 213 of the 387 patients (55%) were alive. One hundred and twenty-eight patients had a follow-up of more than 5 years. The survival probability at 15 years was 38% (32-44, 95% CI).
Second solid tumors
Five patients developed a total of six second solid tumors, 2-13 years after BMT (Table 1) . These comprised one leiomyosarcoma of the small intestine, one osteosarcoma, one adenocarcinoma of the endometrium, one papillary carcinoma of the thyroid gland, one carcinoma in situ of the cervix and one adenocarcinoma of the ovary. Detailed histories of these five patients, including treatment and outcome is given in the respective case reports. Five years after BMT, 128 patients were at risk for developing a second solid tumor, 10 years post transplant 72 patients, and 15 years post transplant 25 patients. The probability of developing a second solid tumor reached 9% (1-17, 95% CI) at 15 years ( Figure 1 ). 
Case 5 (UPN 330):
A 29-year-old women presented with secondary acute myeloid leukemia, occurring 9 years after treatment for Hodgkin's disease. She underwent BMT in second complete remission of the leukemia, receiving T cell-depleted marrow from her HLA-identical sister. Engraftment was supported by the addition of donor buffycoat transfusions between days +1 and +13. Ten years post transplant, at the age of 43, she developed a poorly differentiated ovarian carcinoma, staged FIGO III with peritoneal dissemination and infiltration of the sigmoid. Laparotomy with omentectomy, left hemicolectomy, hysterectomy and adnexectomy was performed, followed by six cycles of chemotherapy with paclitaxel and carboplatin. At last follow-up, 8 months later, she is without evidence of tumor.
Discussion
All five patients with a second solid tumor following allogeneic transplantation entered complete remission and four of the five patients remain alive and well without any sign of their primary and secondary disease 1-10 years after appearance of their tumor.
These five patients were treated at least as intensively as if they had not undergone bone marrow transplantation. The patients with endometrial carcinoma and thyroid carcinoma Bone Marrow Transplantation were treated by surgery and post-operative radiotherapy, the patients with osteosarcoma and ovarian carcinoma with surgery and post-operative chemotherapy and the patient with cervical carcinoma by surgery alone. The patient with the metastatic epitheloid leiomyosarcoma received a very intensive therapeutic regimen, consisting of a double allogeneic transplant. All treatments were tolerated without unexpected toxicity.
There have been a number of reports on the incidence of second solid tumors after BMT 12, 13 but few have focused on treatment. There is little evidence that patients with posttransplant tumors should be treated differently from patients presenting with de novo tumors. General opinion and single reports have created the impression that posttransplant tumors have a very poor prognosis.
14 Fear of limited bone marrow reserve and of excessive organ toxicity are given as arguments to preclude the use of intensive approaches. Socié et al 15 reported the outcome of five patients with solid tumors after BMT for aplastic anemia. Four of them had an unexpectedly difficult course with aggressive tumor growth and early relapse after treatment with standard therapy. One of our patients, who developed a leiomyosarcoma, also relapsed with refractory disease despite prior intensive therapy. Therefore, close monitoring of toxicity, especially hematologic toxicity is warranted in these patients.
The favorable outcome in four of the five patients may be partially due to early tumor stage at diagnosis. In our institution, patients are seen yearly after transplantation. This might explain the early detection of the second tumors. Knowledge of the most frequent type and localization of second tumors, ie mucosal carcinomas, tumors of the thyroid, intestine and oesophagus 16, 17 may help to direct prophylactic clinical examination.
We postulate that second solid tumors after BMT should be treated as intensively as de novo tumors.
